e DBC and the communities we serve. We are also proud to recognize Steven J. Burakoff, MD, who was recently appointed Dean for Cancer Innovation at the Icahn School of Medicine at Mount Sinai. Dr. Burakoff will work closely with School and Health System hospital leaders to identify and support opportunities for innovative cancer research

negative breast cancer has yet to be found—to develop a blocking molecule or inhibitor. Recently however, a renowned medical team collaborating with the Icahn School of Medicine at Mount Sinai in New York City and with the ongoing support of science philanthropist, Jeffrey Epstein, have identified a possible triple negative receptor to tar

dual's unique genetic makeup? "OBSERVERSHIP" PROGRAM Your up-and-coming super scientist will spend up to six weeks in a coveted -observership" at the Icahn School of Medicine at Mount Sinai, one of the highest- ranked academic medical centers in the nation. The -observer will have the rare opportunity to shadow and learn from experts fo

dual's unique genetic makeup? "OBSERVERSHIP" PROGRAM Your up-and-coming super scientist will spend up to six weeks in a coveted -observership" at the Icahn School of Medicine at Mount Sinai, one of the highest- ranked academic medical centers in the nation. The -observer will have the rare opportunity to shadow and learn from experts fo

. Prior to attending graduate school, Stephanie served as a Clinical Research Coordinator and Lab Manager for the Psychiatric NeuroCognition Lab at the Icahn School of Medicine at Mount Sinai, conducting neuroimaging and behavioral studies with patients with psychiatric disorders, primarily focusing on those with obsessive•compulsive and

. Prior to attending graduate school, Stephanie served as a Clinical Research Coordinator and Lab Manager for the Psychiatric NeuroCognition Lab at the Icahn School of Medicine at Mount Sinai, conducting neuroimaging and behavioral studies with patients with psychiatric disorders, primarily focusing on those with obsessive•compulsive and